Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600–mutant anaplastic thyroid cancer

Journal of Clinical Oncology

Volumn 36, Issue 1, 2018, Pages 7-13

  Subbiah, Vivek ^a   Cabanillas, Maria E ^a   Kreitman, Robert J ^b   Wainberg, Zev A ^c   Cho, Jae Yong ^d   Keam, Bhumsuk ^e   Schellens, Jan H M ^f,g   Soria, Jean Charles ^h   Wen, Patrick Y ⁱ   Zielinski, Christoph ^j   Urbanowitz, Gladys ^k   Mookerjee, Bijoyesh ^k   Wang, Dazhe ^k   Rangwala, Fatima ^k  

^a UNIVERSITY OF TEXAS   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Yonsei University College of Medicine   (South Korea)

^e Seoul National University Hospital   (South Korea)

^f NETHERLANDS CANCER INSTITUTE   (Netherlands)

^g UTRECHT UNIVERSITY   (Netherlands)

^h INSTITUT GUSTAVE ROUSSY   (France)

ⁱ DANA FARBER CANCER INSTITUTE   (United States)

^j MEDICAL UNIVERSITY OF VIENNA   (Austria)

^k NOVARTIS PHARMA AG   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; DABRAFENIB; TRAMETINIB; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; OXIME; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE;

ACUTE KIDNEY FAILURE; ADULT; ADVANCED CANCER; AGED; ANAPLASTIC THYROID CARCINOMA; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CLINICAL OUTCOME; CONSTIPATION; COUGHING; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; GENE MUTATION; HEADACHE; HISTOLOGY; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; NAUSEA; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; POPULATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; RHABDOMYOLYSIS; SYSTEMIC THERAPY; TREATMENT RESPONSE; VOMITING; ADOLESCENT; CHEMICALLY INDUCED; CLINICAL TRIAL; DISEASE FREE SURVIVAL; GENETICS; MIDDLE AGED; MUTATION; PATHOLOGY; THYROID CARCINOMA; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; FATIGUE; FEMALE; FEVER; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; MUTATION; NAUSEA; NEOPLASM METASTASIS; OXIMES; PROTO-ONCOGENE PROTEINS B-RAF; PYRIDONES; PYRIMIDINONES; THYROID CARCINOMA, ANAPLASTIC; YOUNG ADULT;

EID: 85039975292     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2017.73.6785     Document Type: Article

References (30)

1. Gilliland FD, Hunt WC, Morris DM, et al: Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) Program 1973-1991. Cancer 79:564-573, 1997
2. Kebebew E, Greenspan FS, Clark OH, et al: Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer 103:1330-1335, 2005
3. Rao SN, Zafereo M, Dadu R, et al: Patterns of treatment failure in anaplastic thyroid carcinoma. Thyroid 27:672-681, 2017
4. National Cancer Institute: SEER Cancer Stat Facts: Thyroid Cancer. https://seer.cancer.gov/statfacts/html/thyro.html
5. Lee DY, Won JK, Choi HS, et al: Recurrence and survival after gross total removal of resectable undifferentiated or poorly differentiated thyroid carcinoma. Thyroid 26:1259-1268, 2016
6. Guerra A, Di Crescenzo V, Garzi A, et al: Genetic mutations in the treatment of anaplastic thyroid cancer: A systematic review. BMC Surg 13:S44, 2013 (suppl 2)
7. Kunstman JW, Juhlin CC, Goh G, et al: Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing. Hum Mol Genet 24:2318-2329, 2015
8. Landa I, Ibrahimpasic T, Boucai L, et al: Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest 126:1052-1066, 2016
9. Sandulache VC, Williams MD, Lai SY, et al: Real-time genomic characterization utilizing circulating cell-free DNA in patients with anaplastic thyroid carcinoma. Thyroid 27:81-87, 2017
10. McIver B, Hay ID, Giuffrida DF, et al: Anaplastic thyroid carcinoma: A 50-year experience at a single institution. Surgery 130:1028-1034, 2001
11. McFadden DG, Vernon A, Santiago PM, et al: p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer. Proc Natl Acad Sci USA 111:E1600-E1609, 2014
12. Flaherty KT, Infante JR, Daud A, et al: Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367:1694-1703, 2012
13. Long GV, Stroyakovskiy D, Gogas H, et al: Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 371: 1877-1888, 2014
14. Long GV, Flaherty KT, Stroyakovskiy D, et al: Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: Long-term survival and safety analysis of a phase 3 study. Ann Oncol 28:1631-1639, 2017
15. Planchard D, Besse B, Groen HJM, et al: Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: An open-label, multicentre phase 2 trial. Lancet Oncol 17:984-993, 2016
16. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
17. Wen PY, Macdonald DR, Reardon DA, et al: Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology Working Group. J Clin Oncol 28:1963-1972, 2010
18. van den Bent MJ, Wefel JS, Schiff D, et al: Response Assessment in Neuro-Oncology (a report of the RANO Group): Assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol 12: 583-593, 2011
19. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982
20. National Cancer Institute: Common Terminology Criteria for Adverse Events (CTCAE) v4.03. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf
21. Daud A, Tsai K: Management of treatment-related adverse events with agents targeting the MAPK pathway in patients with metastatic melanoma. Oncologist 22:823-833, 2017
22. Chakravarty D, Santos E, Ryder M, et al: Small-molecule MAPK inhibitors restore radio-iodine incorporation in mouse thyroid cancers with conditional BRAF activation. J Clin Invest 121: 4700-4711, 2011
23. Charles RP, Iezza G, Amendola E, et al: Mu-tationally activated BRAF(V600E) elicits papillary thyroid cancer in the adult mouse. Cancer Res 71: 3863-3871, 2011
24. Franco AT, Malaguarnera R, Refetoff S, et al: Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice. Proc Natl Acad Sci USA 108:1615-1620, 2011
25. Hyman DM, Puzanov I, Subbiah V, et al: Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med 373:726-736, 2015
26. Ahronian LG, Sennott EM, Van Allen EM, et al: Clinical acquired resistance to RAF inhibitor combinations in BRAF-mutant colorectal cancer through MAPK pathway alterations. Cancer Discov 5:358-367, 2015
27. Johnson DB, Menzies AM, Zimmer L, et al: Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. Eur J Cancer 51:2792-2799, 2015
28. Pietrantonio F, Oddo D, Gloghini A, et al: MET-driven resistance to dual EGFR and BRAF blockade may be overcome by switching from EGFR to MET inhibition in BRAF-mutated colorectal cancer. Cancer Discov 6:963-971, 2016
29. Wagle N, Van Allen EM, Treacy DJ, et al: MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov 4:61-68, 2014
30. Danysh BP, Rieger EY, Sinha DK, et al: Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model. Oncotarget 7: 30907-30923, 2016